%D9%84%D9%82%D8%A7%D8%AD_%D9%81%D9%8A%D8%B1%D9%88%D8%B3_%D9%86%D9%82%D8%B5_%D8%A7%D9%84%D9%85%D9%86%D8%A7%D8%B9%D8%A9_%D8%A7%D9%84%D8%A8%D8%B4%D8%B1%D9%8A%D8%A9HIV-ImpfstoffHIV_vaccineVacuna_contra_el_VIH%D9%88%D8%A7%DA%A9%D8%B3%D9%86_%D8%A7%DA%86%E2%80%8C%D8%A2%DB%8C%E2%80%8C%D9%88%DB%8CHIV-rokoteVacina_contra_o_VIHVaksin_HIVVaccino_contro_l%27HIVHIV%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E0%B4%8E%E0%B4%9A%E0%B5%8D%E0%B4%9A%E0%B5%8D.%E0%B4%90.%E0%B4%B5%E0%B4%BF._%E0%B4%B5%E0%B4%BE%E0%B4%95%E0%B5%8D%E0%B4%B8%E0%B4%BF%E0%B5%BBVaksin_HIV%E0%B8%A7%E0%B8%B1%E0%B8%84%E0%B8%8B%E0%B8%B5%E0%B8%99%E0%B9%80%E0%B8%AD%E0%B8%8A%E0%B9%84%E0%B8%AD%E0%B8%A7%E0%B8%B5%D8%A7%DB%8C%DA%86_%D8%A2%D8%A6%DB%8C_%D9%88%DB%8C_%D9%88%DB%8C%DA%A9%D8%B3%DB%8C%D9%86V%E1%BA%AFc-xin_HIVQ1479804
about
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine targetImmune-correlates analysis of an HIV-1 vaccine efficacy trialThe role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccinationComparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein BoostThe 2017 Keystone Symposium on HIV Vaccines.Structural Sensitivity in HIV Modeling: A Case Study of VaccinationRegulatory T cell abundance and activation status before and after priming with HIVIS-DNA and boosting with MVA-HIV/rgp140/GLA-AF may impact the magnitude of the vaccine-induced immune responsesEfficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNAPositive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing AntibodiesAmantadine Surface-Modified Silver Nanorods Improves Immunotherapy of HIV Vaccine Against HIV-Infected CellsInduction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus VectorThe Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine TemplateAnother HIV vaccine strategy fails in large-scale studyA Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160 (1999-11-02)
P921
Q29547347-456d6eb7-4d0a-ab5a-f0b3-0ea3bb5c8e7cQ29617377-f3c11aed-483a-10a3-df8c-da1e8a19e407Q34291205-31DAC290-3D08-4604-84B8-954F431C5BA7Q35760486-300bea68-4bb8-b3ef-a039-444af43d6d43Q46104275-A0B117F8-BE42-4621-B6F8-7F8922637B52Q61756880-FDD3EEE0-7BF3-40A4-8D3B-855931AA4132Q62489056-099F2C33-AA5D-4CC8-B9AA-132A350DBE9DQ63246643-43FDAEBA-740B-47D9-8697-01D9738A6AA2Q64063774-A6A00F05-F728-433F-9802-41031CA774B1Q64136731-CDD9D47E-C219-485B-B6C2-04FB48AB631AQ64249360-4B28E65E-4EDD-4296-BCF8-AA45BE91A719Q64281085-A1109C39-DDE4-4F17-AA8C-6CDF41C36959Q84369066-5f5b8bbe-473f-d2ec-ba78-af85735ccf54Q86256976-1C9D1D7A-079A-4F41-99B5-3983EE3A3299
P921
description
in-progress vaccinations that may prevent or treat HIV infections
@en
name
HIV vaccine
@en
HIV-Impfstoff
@de
HIV-rokote
@fi
HIVワクチン
@ja
HIV病毒疫苗
@zh-hant
Vaccino HIV
@it
Vacina contra o VIH
@gl
Vacuna contra el VIH
@es
Vaksin HIV
@id
Vaksin HIV
@ms
type
label
HIV vaccine
@en
HIV-Impfstoff
@de
HIV-rokote
@fi
HIVワクチン
@ja
HIV病毒疫苗
@zh-hant
Vaccino HIV
@it
Vacina contra o VIH
@gl
Vacuna contra el VIH
@es
Vaksin HIV
@id
Vaksin HIV
@ms
altLabel
AIDS Vaccines
@en
HIV vaccine
@th
hiv-vaksine
@nn
vaksine mot hiv
@nn
วัคซีนป้องกันการติดเชื้อเอชไอวี
@th
prefLabel
HIV vaccine
@en
HIV-Impfstoff
@de
HIV-rokote
@fi
HIVワクチン
@ja
HIV病毒疫苗
@zh-hant
Vaccino HIV
@it
Vacina contra o VIH
@gl
Vacuna contra el VIH
@es
Vaksin HIV
@id
Vaksin HIV
@ms
P244
P486
P6366
P646
P1924
P244
sh88007929
P279
P3827
aids-vaccines
P486
P6366
2780195530